Poly(ADP-Ribose)Polymerase-1 in Lung Inflammatory Disorders: A Review.

Sethi, GS; Dharwal, V; Naura, AS

Poly(ADP-Ribose)Polymerase-1 in Lung Inflammatory Disorders: A Review.

Sethi, GS Dharwal, V

Naura, AS

Permalink

Publisher:: Frontiers Media
Publication Type:: Journal Article
Citation:: Frontiers in Immunology, 2017, 8, (SEP), pp. 1-18
Issue Date:: 2017

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download full textAdobe PDF (1.43 MB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Sethi, GS
dc.contributor.author	Dharwal, V https://orcid.org/0000-0002-9645-3797
dc.contributor.author	Naura, AS
dc.date.accessioned	2022-07-08T03:38:44Z
dc.date.available	2017-09-04
dc.date.available	2022-07-08T03:38:44Z
dc.date.issued	2017
dc.identifier.citation	Frontiers in Immunology, 2017, 8, (SEP), pp. 1-18
dc.identifier.issn	1664-3224
dc.identifier.issn	1664-3224
dc.identifier.uri	http://hdl.handle.net/10453/158753
dc.description.abstract	Asthma, acute lung injury (ALI), and chronic obstructive pulmonary disease (COPD) are lung inflammatory disorders with a common outcome, that is, difficulty in breathing. Corticosteroids, a class of potent anti-inflammatory drugs, have shown less success in the treatment/management of these disorders, particularly ALI and COPD; thus, alternative therapies are needed. Poly(ADP-ribose)polymerases (PARPs) are the post-translational modifying enzymes with a primary role in DNA repair. During the last two decades, several studies have reported the critical role played by PARPs in a good of inflammatory disorders. In the current review, the studies that address the role of PARPs in asthma, ALI, and COPD have been discussed. Among the different members of the family, PARP-1 emerges as a key player in the orchestration of lung inflammation in asthma and ALI. In addition, PARP activation seems to be associated with the progression of COPD. Furthermore, PARP-14 seems to play a crucial role in asthma. STAT-6 and GATA-3 are reported to be central players in PARP-1-mediated eosinophilic inflammation in asthma. Interestingly, oxidative stress-PARP-1-NF-κB axis appears to be tightly linked with inflammatory response in all three-lung diseases despite their distinct pathophysiologies. The present review sheds light on PARP-1-regulated factors, which may be common or differential players in asthma/ALI/COPD and put forward our prospective for future studies.
dc.format	Electronic-eCollection
dc.language	eng
dc.publisher	Frontiers Media
dc.relation.ispartof	Frontiers in Immunology
dc.relation.isbasedon	10.3389/fimmu.2017.01172
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	1107 Immunology, 1108 Medical Microbiology
dc.title	Poly(ADP-Ribose)Polymerase-1 in Lung Inflammatory Disorders: A Review.
dc.type	Journal Article
utslib.citation.volume	8
utslib.location.activity	Switzerland
utslib.for	1107 Immunology
utslib.for	1108 Medical Microbiology
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Science
utslib.copyright.status	open_access	*
pubs.consider-herdc	false
dc.date.updated	2022-07-08T03:38:41Z
pubs.issue	SEP
pubs.publication-status	Published
pubs.volume	8
utslib.citation.issue	SEP

Abstract:

Asthma, acute lung injury (ALI), and chronic obstructive pulmonary disease (COPD) are lung inflammatory disorders with a common outcome, that is, difficulty in breathing. Corticosteroids, a class of potent anti-inflammatory drugs, have shown less success in the treatment/management of these disorders, particularly ALI and COPD; thus, alternative therapies are needed. Poly(ADP-ribose)polymerases (PARPs) are the post-translational modifying enzymes with a primary role in DNA repair. During the last two decades, several studies have reported the critical role played by PARPs in a good of inflammatory disorders. In the current review, the studies that address the role of PARPs in asthma, ALI, and COPD have been discussed. Among the different members of the family, PARP-1 emerges as a key player in the orchestration of lung inflammation in asthma and ALI. In addition, PARP activation seems to be associated with the progression of COPD. Furthermore, PARP-14 seems to play a crucial role in asthma. STAT-6 and GATA-3 are reported to be central players in PARP-1-mediated eosinophilic inflammation in asthma. Interestingly, oxidative stress-PARP-1-NF-κB axis appears to be tightly linked with inflammatory response in all three-lung diseases despite their distinct pathophysiologies. The present review sheds light on PARP-1-regulated factors, which may be common or differential players in asthma/ALI/COPD and put forward our prospective for future studies.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/158753